Kvyat to race at home F1 GP in Sochi with new helmet design depicting him riding torpedoSport April 27, 21:43
Maria Sharapova gets into quarterfinal of tournament in StuttgartSport April 27, 21:16
Russia, Japan to hold bilateral year of culture in 2018World April 27, 20:49
Angela Merkel’s visit to Moscow – pragmatism above all elseRussian Politics & Diplomacy April 27, 19:18
Japanese businessmen and officials to visit South Kuril Islands in summerWorld April 27, 18:46
Putin, Abe call for quickest restart of talks on Korean settlementRussian Politics & Diplomacy April 27, 18:32
Russian diplomat accuses White Helmets of supporting terrorismRussian Politics & Diplomacy April 27, 17:54
Putin's spokesman warns against attempts to hold unauthorized rallies in MoscowRussian Politics & Diplomacy April 27, 16:43
Russian Foreign Ministry says situation on Korean Peninsula is degradingRussian Politics & Diplomacy April 27, 16:42
MOSCOW, December 23. /TASS/. An experimental Ebola vaccine proved to be highly protective against the deadly virus in a major trial in Guinea, the World Health Organization announced in a statement Friday.
"While these compelling results come too late for those who lost their lives during West Africa's Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," said Dr Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation, who is also the study’s lead author.
The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.
The vaccine was manufactured by Merck, Sharpe & Dohme (MSD).
According to the WHO, more than 11,000 people died during the 2014-2015 Ebola outbreak in West Africa. Most fatalities occurred in Liberia, Sierra-Leone and Guinea.